Key Takeaways & Executive Findings
- •• Combination therapy (e.g., atezolizumab plus bevacizumab) significantly improves overall survival and progression-free survival in unresectable hepatocellular carcinoma compared to sorafenib. • Objective response rates are more than doubled with combination therapy, indicating enhanced antitumor activity. • The increased risk of grade ≥3 adverse events is manageable with appropriate monitoring and supportive care. • These results establish combination therapy as a new first-line standard for unresectable HCC, potentially improving long-term outcomes.
Abstract
Background: Unresectable hepatocellular carcinoma (HCC) remains a therapeutic challenge. Combination therapy with anticancer drugs has shown promise, but its overall efficacy and safety profile requires systematic evaluation. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing combination therapy (e.g., atezolizumab plus bevacizumab) versus standard of care (sorafenib) in patients with unresectable HCC. Primary outcomes were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Secondary outcomes included adverse events (AEs). Results: A total of 12 RCTs involving 5,847 patients were included. Combination therapy significantly improved OS (HR 0.66, 95% CI 0.58-0.75), PFS (HR 0.58, 95% CI 0.49-0.68), and ORR (RR 2.14, 95% CI 1.72-2.66) compared to sorafenib. The incidence of grade ≥3 AEs was higher with combination therapy (RR 1.24, 95% CI 1.08-1.42), but manageable. Subgroup analyses showed consistent benefits across different treatment regimens and patient characteristics. Conclusion: Combination therapy with anticancer drugs significantly improves survival outcomes in unresectable HCC, albeit with increased but manageable toxicity. These findings support its use as a new standard of care.
1. Introduction
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancer-related mortality worldwide. Despite advances in screening and treatment, a significant proportion of patients present with unresectable disease, either due to advanced stage or poor liver function. Historically, systemic therapy options were limited, with sorafenib being the only effective agent for over a decade. However, its efficacy is modest, and the prognosis for patients with unresectable HCC remains poor.
In recent years, the advent of immune checkpoint inhibitors and anti-angiogenic agents has revolutionized the treatment landscape of HCC. Combination strategies, such as atezolizumab plus bevacizumab, have demonstrated promising results in clinical trials, leading to regulatory approvals. Nevertheless, the magnitude of benefit and the safety profile of these combinations compared to standard of care need to be systematically quantified to inform clinical decision-making. This systematic review and meta-analysis aims to synthesize evidence from randomized controlled trials to evaluate the efficacy and safety of combination therapy with anticancer drugs in unresectable HCC.
Loading authentic research manuscript (Pages 1–5)...
Zhang Wei, Li Ming, Wang Fang, Chen Jing, Liu Yang (2026). Efficacy and Safety of Combination Therapy with Anticancer Drugs in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-025-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the standard of care for unresectable hepatocellular carcinoma?
Historically, sorafenib was the standard first-line systemic therapy for unresectable HCC. However, recent combination therapies, such as atezolizumab plus bevacizumab, have shown superior efficacy and are now recommended as preferred first-line options.
How does combination therapy improve outcomes in HCC?
Combination therapy, typically involving an immune checkpoint inhibitor and an anti-angiogenic agent, works synergistically to enhance antitumor immunity and inhibit tumor angiogenesis, leading to improved overall survival, progression-free survival, and objective response rates compared to sorafenib.
What are the common adverse events of combination therapy?
Common adverse events include hypertension, fatigue, elevated liver enzymes, and immune-related events such as rash and colitis. Grade ≥3 adverse events are more frequent with combination therapy but are generally manageable with dose adjustments and supportive care.
Is combination therapy suitable for all patients with unresectable HCC?
Patient selection is crucial. Factors such as liver function, performance status, and comorbidities should be considered. Combination therapy is generally recommended for patients with preserved liver function and good performance status, but individual risk-benefit assessment is essential.
What are the future directions for HCC treatment?
Ongoing research focuses on identifying biomarkers to predict response, optimizing treatment sequences, and exploring novel combinations, including triplet therapies and combinations with local-regional treatments, to further improve outcomes.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.